United Therapeutics price target raised to $75 from $65 at Argus Argus increased its price target on United Therapeutics after the company reported higher than expected Q4 EPS. The firm continues to believe that the company will generate strong long-term growth, and it maintains a Buy rating.
News For UTHR From The Last 14 Days
Check below for free stories on UTHR the last two weeks.
Deutsche Bank to host a conference BioFest is being held in Boston on December 2-3 with webcasted company presentations to begin on December 3 at 7:50 am; not all company presentations may be webcasted. Webcast Link
United Therapeutics price target raised to $110 from $85 at Argus Argus increased its price target on United Therapeutics as the firm believes that the company reported solid Q3 results and should benefit from launches of its Remodulin treatment in overseas markets. The firm keeps a Buy rating on the stock.